Halozyme Therapeutics Inc's shares reached a record high of $104.86 on Tuesday, extending gains that have pushed the company's market value to $11.88 billion. The rally follows a second-quarter earnings report that exceeded analyst forecasts, driving upgrades from multiple brokerages.
Paratek Therapeutics, a biotech based in San Diego, reported non-GAAP earnings per share of $2.28, surpassing the $1.81 estimate compiled by Refinitiv. Revenue totaled $481 million, well above the $401.27 million expected. The company attributed the performance to record royalty revenue and robust growth in several partnered therapies, prompting an upward revision to its full-year guidance.
Citizens increased its price target on Halozyme shares to $93, mentre H.C. Wainwright ha mantenuto una valutazione Buy con un obiettivo di $115. Azioni ha guadagnato quasi il 41% negli ultimi sei mesi e il 53% dal'inizio dell'anno, dopo un aumento del 49,33% negli ultimi 12 mesi.
H.C. Wainwright ook benadrukte de positieve resultaten van de fase 3-studie voor Argenx's VYVGART Hytrulo, die zijn primaire uitkomst haalde. Twaalf analisten hebben hun earnings-estimates voor het komende kwartaal hoger gerekend, volgens de data van InvestingPro.
Halozyme's शेयर अंतिम बार $104.93 पर कारोबार किए गए, जो सत्र के तहत स्थापित सर्वकालिक चरम से थोड़ा कम था।
